KAMA FLOW инвестирует 600 млн рублей в «Рапид Био»

KAMA FLOW invests RUB 600 million in Rapid Bio 🧬

The funds will be used to develop new diagnostic platforms and expand the product portfolio — from reproductive health tests to solutions in oncology, neurology, and genetics. The financing agreement was signed at the Moscow Startup Summit.

What you need to know about Rapid Bio:

•  More than 30 ready-to-market products and around 90 developments in its portfolio.
•  Five R&D laboratories in Moscow and St. Petersburg, with more than 60 biotech specialists.
•  Production capacity of up to 180 million tests per year.
•  Key technology areas include immunochromatography, enzyme-linked immunosorbent assay (ELISA), microfluidics, and next-generation sequencing (NGS).

The company started by developing rapid tests for diagnosing brain injuries and, in 2020, became the first Russian manufacturer to launch its own COVID-19 rapid tests. Today, Rapid Bio is expanding its product portfolio. New areas include embryo genetic screening, oncology, cardiology, and reproductive health. Registration of the first products from the new portfolio is planned for 2027.

Sergey Gaivoronsky, Investment Director at KAMA FLOW: “For us, Rapid Bio is an investment in a team that knows how to turn scientific expertise into commercial products. The company reinvested the profits generated during the pandemic into its research infrastructure, manufacturing capabilities, and new technology platforms, and has already demonstrated its ability to bring developments to market. We are also attracted by its model of entering new segments through partnerships with major strategic players, as well as its experience in international markets. KAMA FLOW’s investment round will enable the company to continue its R&D efforts and accelerate the launch of its next product portfolio.”

 Anzhey Zhimbiev, CEO and Founder of the Rapid Bio group of companies: “Over many years, our country has built outstanding scientific expertise and the potential to create unique medical innovations that can be competitive both in Russia and internationally. Despite this, most medical devices are still imported. I see significant opportunities for Rapid Bio to become a technology leader in diagnostics by investing in its own technology platforms, replacing foreign alternatives, and deliberately expanding into the markets of Africa, Southeast Asia, and other regions.”

Read more about the deal in Kommersant.